Latest Breaking News On - Debra odink - Page 1 : comparemela.com

Thryv Therapeutics - 2023 Year End Report

Thryv Therapeutics Inc. Announces the Appointment of Dr. Debra Odink to President and Dr. Shi Yin Foo to the Board of Directors

/PRNewswire/ - Thryv Therapeutics Inc. is pleased to announce the appointment of Dr. Debra Odink to President and Chief Development Officer of the company and.

Expanding Pipeline Leads to Name Change LQT Therapeutics Now Thryv Therapeutics

New Name Emphasizes Relentless Pursuit of an Expanded and Rare Disease Portfolio Oncology Programs added to existing Long QT Syndrome Program ( LQ.

Expanding Pipeline Leads to Name Change LQT Therapeutics Now Thryv Therapeutics

/PRNewswire/ - Thryv Therapeutics Inc. is excited to announce the evolution of its portfolio to include treatments for resistant and rare cancers. The new.

LQT Therapeutics Announces Award by the European Joint Program for Rare Diseases for SGK1 inhibition as a novel therapeutic approach in Long QT syndrome

/PRNewswire/ - LQT Therapeutics, a privately-held biopharmaceutical company advancing novel SGK1 kinase therapeutics, today announced that the project.